Advertisement

U.S. markets open in 8 hours 4 minutes

S&P Futures
5,888.75
-3.75(-0.06%)
Dow Futures
43,049.00
-120.00(-0.28%)
Nasdaq Futures
20,525.25
-16.75(-0.08%)
Russell 2000 Futures
2,244.60
-1.60(-0.07%)
Crude Oil
72.24
+0.15(+0.21%)
Gold
2,763.70
+3.90(+0.14%)

Kezar Life Sciences, Inc. (KZR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

0.7800

-0.0123

(-1.55%)

At close: 04:00PM EDT

0.7805

+0.00

(+0.06%)

After hours:

04:15PM EDT

Trade prices are not sourced from all markets

All

Clinical Trials Arena
Kezar Life Sciences discontinues lupus nephritis programme after fatalities
Kezar’s decision to terminate the PALIZADE IIb trial comes after it was placed on a clinical hold due to four patient deaths.
Benzinga
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study
On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active lupus nephritis (LN) and focus clinical development efforts on zetomipzomib in autoimmune hepatitis (AIH). Last week, the FDA placed a clinical hold on the company’s zetomipzomib Investigational New Drug (IND) application for LN following a review of emerging safety data, including an assessment of four Grade 5 (fatal or death) serious adverse events (SAEs) that occurred du